Issues
-
Cover Image
Cover Image
Somatic mosaicism, where two or more cell populations have different genotypes, can occur in normal cells as they undergo mutagenesis over an individual's life span. These mosaic variants can arise early in embryogenesis and be present in adult tissues. Mosaicism in cancer susceptibility genes has been observed in individuals with clinical features of hereditary predisposition syndromes, but the contribution of these mosaic variants to the development of apparently sporadic cancers has yet to be defined. Pareja, Ptashkin, Brown, and colleagues analyzed paired tumor/blood sequencing data from over 35,000 unselected patients with cancer and showed that mosaic variants affecting cancer susceptibility genes can occur early in embryogenesis and are likely to contribute to tumorigenesis, thereby increasing the risk for developing cancer. The detection of these variants may ultimately influence clinical decisions as well as preventive measures for patients and their offspring. For more information, see the article by Pareja, Ptashkin, Brown, and colleagues on page 949. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
In This Issue
In the Spotlight
In Focus
Reviews
Research Briefs
Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program
Cancer-Causative Mutations Occurring in Early Embryogenesis
Research Articles
The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals
In both healthy and cancer-bearing individuals, Th1/Tc1 response of spike protein–specific memory T cells is associated with susceptibility to SARS-CoV-2 infection.
Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer
The S100A9–ALDH1A1–retinoic acid signaling pathway mediates osimertinib resistance and brain relapse in models of EGFR-mutant lung cancer.
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
The polyphenol castalagin acts as a prebiotic and exerts antitumor activity as well as potentiates anti–PD-1 immune efficacy through a beneficial shift in microbiome composition.
Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti–PD-1 Therapy
Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia
Kynurenine secreted by acute myeloid leukemia cells activates the serotonin receptor 1b in osteoblasts to drive leukemia through the acute-phase protein serum amyloid A (SAA), with an increase in both kynurenine and SAA seen in mouse models and patient samples.
Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis
Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation
NUP98 fusion oncoproteins promote leukemogenesis by undergoing phase separation in the nuclei of hematopoietic cells to form hundreds of punctate transcriptional condensates that drive aberrant gene expression and induce myeloid transformation.
News in Brief
Research Watch
Drug Resistance
Immunotherapy
Viruses
Brain Tumors
Genome-Wide Association Studies
Pancreatic Cancer
Combination Therapy
Microbiome
Pancreatic Cancer
Glioblastoma
Clinical Trials
Immunology
Metastasis
Extracellular Matrix
Biotechnology
Drug Evaluation
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.